Mechanism-Based Inactivation of Cytochrome P450 3A4 by 4-Ipomeanol

Chemical Research in Toxicology

Volumn 17, Issue 2, 2004, Pages 150-157

  Alvarez Diez, Teresa M ^a   Zheng, Jiang ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 IPOMEANOL; CATALASE; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; CYTOCHROME P450 REDUCTASE; DRUG METABOLITE; GLUTATHIONE; LIVER ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE DISMUTASE; TESTOSTERONE;

ARTICLE; BINDING ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; CULTURE MEDIUM; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME MODIFICATION; ENZYME SUBSTRATE; HUMAN; ISOTOPE LABELING; LIVER MICROSOME; LIVER TOXICITY; PARTITION COEFFICIENT; PATHOPHYSIOLOGY; STOICHIOMETRY; TOXICITY TESTING; TOXIN ANALYSIS;

CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; NADP; SUBSTRATE SPECIFICITY; TERPENES;

EID: 1342310586     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx034143l     Document Type: Article

References (57)

1. Boyd, M. R., and Wilson, B. J. (1972) Isolation and characterization of 4-ipomeanol, a lung-toxic furanoterpenoid produced by sweet potatoes (Ipomoea batatas). J. Agric. Food Chem. 20 (2), 428-430.
2. Boyd, M. R., Wilson, B. J., and Harris, T. M. (1972) Confirmation by chemical synthesis of the structure of 4-ipomeanol, a lung-toxic metabolite of the sweet potato, Ipomoea batatas. Nat. New Biol. 236, 158-159.
3. Doster, A. R., Mitchell, F. E., and Farrell, R. L. (1978) Effects of 4-ipomeanol, a product from mold-damaged sweet potatoes, on bovine lung. Vet. Pathol. 15, 367-575.
4. Durham, S. K., Boyd, M. R., and Castelman, W. L. (1985) Pulmonary endothelial and bronchiolar epithelial lesions induced by 4-ipomeanol in mice. Am. J. Pathol. 118, 66-75.
5. Gram, T. E. (1989) Pulmonary toxicity of 4-ipomeanol. Pharmacol. Ther. 43, 291-297.
6. Boyd, M. R. (1977) Evidence for the Clara cells as a site of cytochrome P450-dependent mixed-function oxidase activity in lung. Nature 269, 7130-7150.
7. Larson, P., and Tjalve, H. (1988) Tracing tissues with 4-ipomeanol-metabolizing capacity in rats. Chem-Biol. Interact. 67, 1-24.
8. Boyd, M. R., Stiko, A., Statham, C. N., and Jones, R. B. (1982). Protective role of endogenous pulmonary glutathione and other sulfhydryl compounds against lung damage by alkylating agents: investigations of 4-ipomeanol in the rat. Biochem. Pharmacol. 31, 1579-1583.
9. Buckpitt, A. R., and Boyd, M. R. (1980) The in vitro formation of glutathione conjugates with the microsomally activated pulmonary bronchiolar alkylating agent and cytotoxin, 4-ipomeanol. J. Pharmacol. Exp. Ther. 215, 97-103.
10. Verschoyle, R. D., Philpot, R. M., and Dinsdale, D. (1993) CYP4B1 activates 4-ipomeanol in rat lung. Toxicol. Appl. Pharmacol. 123, 193-198.
11. Wolf, C. R., Statham, C. N., and McMenamin, M. G. (1982) The relationship between the catalytic activities in rabbit pulmonary cytochrome P450 isozymes and the lung-specific toxicity of the furan derivative, 4-ipomeanol. Mol. Pharmacol. 22, 738-744.
12. Boyd, M. R., and Burka, L. T. (1978) In vivo studies on the relationship between target organ alkylation and the pulmonary toxicity of a chemically reactive metabolite of 4-ipomeanol. J. Pharmacol. Exp. Therap. 207 (3), 687-697.
13. Boyd, M. R., Burka, L. T., and Wilson, B. J. (1978) In vitro studies on the metabolic activation of the pulmonary toxin, 4-ipomeanol, by rat lung and liver microsomes. J. Pharmacol. Exp. Therap. 207 (3), 677-686.
14. Slaugther, S. R., Staham, C. N., and Philpot, R. M. (1983) Covalent binding of metabolites of 4-ipomeanol to rabbit pulmonary and hepatic microsomal proteins and to the enzymes of the pulmonary P-450 dependent monooxygenase system. J. Pharmacol. Exp. Ther. 224, 252-257.
15. Dutcher, J. S., and Boyd, M. R. (1979) Species and strain differences in target organ alkylation and toxicity by 4-ipomeanol. Biochem. Pharmacol. 28, 3367-3372.
16. Chrisian, M. C., Wittes, R., and Leyland-Jones B. (1989) 4-Ipomeanol: A novel investigational new drug for lung cancer. J. Natl. Cancer Inst. 81, 1133-1143.
17. Falzon, M.-m., and McMahon, J. B. (1986) Metabolic activation and cytotoxicity of 4-ipomeanol in human nonsmall cell lung cancer lines. Cancer Res. 46, 3484-3489.
18. McLemore, T., Coudert, B., and Adelberg, S. (1988) Metabolic activation of 4-ipomeanol by human pulmonary carcinoma cells propagated in vitro and intrabronchially in nude mice. Clin. Res. 36, 498A.
19. Rowinsky, E. K., Noe, D. A., and Ettinger, D. S. (1993) Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients; hepatotoxicity is dose limiting in humans. Cancer Res. 53, 1794-1801.
20. Kasturi, V. J., Dearing, M. P., and Piscitelli, S. C. (1998) Phase I study of a five-day dose schedule of 4-ipomeanol in patients with nonsmall cell lung cancer. Clin. Cancer Res. 4, 2095-2102.
21. Lakhanpal, S., Donehover, R. C., and Rowinsky, E. K. (2001) Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma. Invest. New Drugs 19 (1), 69-76.
22. Mohr, L., Rainov, N. G., Mohr, U. G., and Wands, J. R. (2000) Rabbit cytochrome P450 4B1: a novel prodrug bioactivating gene for pharmacogene therapy of hepatocellular carcinoma. Cancer Gene Ther. 7 (7), 1008-1014.
23. Rainov, N. G., Dobberstein, K.-U., and Sena-Estevens, M. (1998) New prodrug activation gene therapy for cancers using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum. Gene Ther. 9 (9), 1261-1273.
24. Czerwinski, M., McLemore, T. L., and Philpot, R. M. (1991) Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochrome P-450: evidence for species-specific metabolism. Cancer Res. 51, 4636-4638.
25. Sahali-Sahly, Y., Balani, S. K., Lin, J. H., and Baillie, T. A. (1996) In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4. Chem. Res. Toxicol. 9, 1007-1012.
26. Lightning, L. K., Jones, J. P., and Friedberg, T. (2000) Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394. Biochemistry 39 (15), 4276-4287.
27. Khojasteh-Bakht, S. C., Koenigs, L. L., and Peter, R. M. (1998) R-(+)-Menthofuran is a potent mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab. Dispos. 26 (7), 701-704.
28. Racha, J. K., Rettie, A., and Kunze, K. L. (1998) Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline. Detection of a 1:1 adduct to protein and evidence of formation of a novel imidazomethide intermediate. Biochemistry 37, 7407-7419.
29. Koenigs, L., and Trager, W. F. (1998) Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochemistry 37, 10004-10061.
30. Statham, C. N., and Boyd, M. R. (1982) Effects of phenobarbital and 3-methylcholanthrene on the in vivo distribution, metabolism and covalent binding of 4-ipomeanol in the rat; implications for target organ toxicity. Biochem. Pharmacol. 24, 3973-3977.
31. Boyd, M. R., Sasame H. A., and Frankin R. B. (1980) Comparison of ratios of covalent binding to total metabolism of the pulmonary toxin, 4-ipomeanol, in vitro in pulmonary and hepatic microsomes and the effects of pretreatment with Phenobarbital or 3-methylchlolanthrene. Biochem. Biophys. Res. Commun. 193, 1167-1172.
32. Klaassen, C. D., Amdur, M. O., and Doull, J., Eds. (1986) Biotransformation of xenobiotics. In Casarett and Doull's Toxicology, the Basic Science of Poisons, pp 113-186, McGraw-Hill, New York.
33. Wrighton, S. A., Schuetz, E. G., and Thummel, K. E. (2000) The human CYP3A subfamily: practical considerations. Drug Metab. Rev. 32 (3, 4), 339-361.
34. von-Moltke, L., Greenblatt, D. J., and Schmider, J. (1995) Metabolism of drugs by cytochrome P450 3A isoforms. Clin. Pharmacokinet. 29 (Suppl. 1), 33-44.
35. Maurel, P. (1996) The CYP3 family. In Cytochromes P450: Metabolic and Toxicological Aspects (Ioannides, C., Ed.) pp 241-395, CRC Press Inc., Boca Raton, FL.
36. Guengerich, F. P. (1995) Human cytochrome P-450. In Cytochrome P-450: Structure, Mechanism and Biochemistry (Ortiz de Montellano, P. R., Ed.) pp 473-535, Plenum Press, New York.
37. Wang, R. W., Newton, D. J., and Scheri, T. D. (1997). Human cytochrome P450 3A4 catalyzes testosterone 6-hydorxylation and erythromycin N-demethylation. Drug Metab. Dispos. 25 (4), 502-507.
38. Ketter, T. A.-M., Flockhart, D. A., and Post, R. M. (1995) The emerging role of cytochrome P450 3A in psychopharmacology. J. Clin. Phychopharmacol. 15 (6), 387.
39. Kenworthy, K. E., Bloomer, J. C., Clarke, S. E., and Houston, J. B. (1999) CYP3A4 drug interactions: correlations of 10 in vitro probe substrates. Br. J. Clin. Pharmacol. 48, 716-722.
40. Waxman, D. J., Attisano, C., and Guengerich, F. P. (1988). Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6-b-hydroxylase cytochrome P450 enzyme. Arch. Biochem. Biophys. 263 (2), 425-436.
41. Pritchard, M. P., Ossetian, R., Li, D. N., and Henderson, C. J. (1997) A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6 and CYP2E1. Arch. Biochem. Biophys. 345, 342-354.
42. Shen, A. L., Porter, T., Wilson, T., and Kasper, C. B. (1989) Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. J. Biol. Chem. 264 (13), 7584-7589.
43. Shen, A. L., Christensen, M. J., and Kasper, C. B. (1991) NADPH-Cytochrome P-450 Oxidoreductase. J. Biol. Chem. 266 (30), 19976-19980.
44. Boyd, M. R., Burka, L. T., and Harris, L. T. (1973) Lung-toxic furanoterpenoids produced by sweet potatoes (Ipomoea batatas) following microbial infection. Biochim. Biophys. Acta 337, 184-195.
45. Silverman, R. B. (1998) Introduction. Mechanism-Based Inactivation: Chemistry and Enzymology, Vol. I, pp 3-30, CRC Press, New York.
46. Miller Miller, V. P., Stresser, D. M., and Blanchard, A. P. (2000) Fluorometric high-throughput screening for inhibitors of cytochrome P450. Ann. N. Y. Acad. Sci. 26-32.
47. Ute, M. K., Jushchyshyn, M. I., and Hollenberg, P. F. (2001) Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr. Drug Metab. 2, 215-243.
48. Kitz, R., and Wilson, I. B. (1962) Esters of Methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J. Biol. Chem. 227 (10), 3245-3249.
49. Wang, E., and Walsh, C. (1978) Suicide substrate for the alanine racemase of Escherichia coli B. Biochemistry 17, 1313-1321.
50. Slaugther, S. R., Staham, C. N., and Philpot, R. M. (1983) Covalent binding of metabolites of 4-ipomeanol to rabbit pulmonary and hepatic microsomal proteins and to the enzymes of the pulmonary P-450 dependent monooxygenase system. J. Pharmacol. Exp. Ther. 224, 252-257.
51. Kobayashi, T., Sugihara, J., and Harigaya S. (1987) Mechanism of metabolic cleavage of a furan ring. Drug Metab. Dispos. 15 (6), 877-881.
52. Chen, L.-J., Hecht, S. S., and Peterson, L (1995) Identification of cis-2-butene-1,4-dial as a microsomal metabolite of furan. Chem. Res. Toxicol. 8, 903-906.
53. Khojateh-Bakht, S. C., Chen, W., and Koenings, L. L. (1999) Metabolism of (R)-(+)-menthofuran by human liver cytochrome P-450s: evidence for formation of a furan epoxide. Drug Metab. Dispos. 27 (5), 574-580.
54. Ravindranath, V., Burka, L. T., and Boyd, M. R. (1984) Reactive metabolites from the bioactivation of toxic methylfurans. Science 224, 884-886.
55. Ravindranath, V., and Boyd, M. R. (1985) Metabolic activation of 2-methylfuran by rat microsomal systems. Toxicol. Appl. Pharmacol. 78, 370-376.
56. Dalvie, D. K., Kalgutkar, A. S., Khojasteh-Bakht, S. C., Obach, R. S., and O'Donnell, J. P. (2002) Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem. Res. Toxicol. 15, 269-299.
57. Monks, T. J., and Lau, S. S. (1988) Reactive intermediates and their toxicological significance. Toxicology 52, 1-53.